Yu-Lin Sun1, Jian-Qiang Cai1, Fang Liu1, Xin-Yu Bi1, Lan-Ping Zhou1, Xiao-Hang Zhao1. 1. Yu-Lin Sun, Fang Liu, Lan-Ping Zhou, Xiao-Hang Zhao, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
AIM: To investigate the expression characteristics of peroxiredoxin 1 (PRDX1) mRNA and protein in liver cancer cell lines and tissues. METHODS: The RNA sequencing data from 374 patients with liver cancer were obtained from The Cancer Genome Atlas. The expression and clinical characteristics of PRDX1 mRNA were analyzed in this dataset. The Kaplan-Meier and Cox regression survival analysis was performed to determine the relationship between PRDX1 levels and patient survival. Subcellular fractionation and Western blotting were used to demonstrate the expression of PRDX1 protein in six liver cancer cell lines and 29 paired fresh tissue specimens. After bioinformatics prediction, a putative post-translational modification form of PRDX1 was observed using immunofluorescence under confocal microscopy and immunoprecipitation analysis in liver cancer cells. RESULTS: The mRNA of PRDX1 gene was upregulated about 1.3-fold in tumor tissue compared with the adjacent non-tumor control (P = 0.005). Its abundance was significantly higher in men than women (P < 0.001). High levels of PRDX1 mRNA were associated with a shorter overall survival time (P = 0.04) but not with recurrence-free survival. The Cox regression analysis demonstrated that patients with high PRDX1 mRNA showed about 1.9-fold increase of risk for death (P = 0.03). In liver cancer cells, PRDX1 protein was strongly expressed with multiple different bands. PRDX1 in the cytosol fraction existed near the theoretical molecular weight, whereas two higher molecular weight bands were present in the membrane/organelle and nuclear fractions. Importantly, the theoretical PRDX1 band was increased, whereas the high molecular weight form was decreased in tumor tissues. Subsequent experiments revealed that the high molecular weight bands of PRDX1 might result from the post-translational modification by small ubiquitin-like modifier-1 (SUMO1). CONCLUSION: PRDX1 was overexpressed in the tumor tissues of liver cancer and served as an independent poor prognostic factor for overall survival. PRDX1 can be modified by SUMO to play specific roles in hepatocarcinogenesis.
AIM: To investigate the expression characteristics of peroxiredoxin 1 (PRDX1) mRNA and protein in liver cancer cell lines and tissues. METHODS: The RNA sequencing data from 374 patients with liver cancer were obtained from The Cancer Genome Atlas. The expression and clinical characteristics of PRDX1 mRNA were analyzed in this dataset. The Kaplan-Meier and Cox regression survival analysis was performed to determine the relationship between PRDX1 levels and patient survival. Subcellular fractionation and Western blotting were used to demonstrate the expression of PRDX1 protein in six liver cancer cell lines and 29 paired fresh tissue specimens. After bioinformatics prediction, a putative post-translational modification form of PRDX1 was observed using immunofluorescence under confocal microscopy and immunoprecipitation analysis in liver cancer cells. RESULTS: The mRNA of PRDX1 gene was upregulated about 1.3-fold in tumor tissue compared with the adjacent non-tumor control (P = 0.005). Its abundance was significantly higher in men than women (P < 0.001). High levels of PRDX1 mRNA were associated with a shorter overall survival time (P = 0.04) but not with recurrence-free survival. The Cox regression analysis demonstrated that patients with high PRDX1 mRNA showed about 1.9-fold increase of risk for death (P = 0.03). In liver cancer cells, PRDX1 protein was strongly expressed with multiple different bands. PRDX1 in the cytosol fraction existed near the theoretical molecular weight, whereas two higher molecular weight bands were present in the membrane/organelle and nuclear fractions. Importantly, the theoretical PRDX1 band was increased, whereas the high molecular weight form was decreased in tumor tissues. Subsequent experiments revealed that the high molecular weight bands of PRDX1 might result from the post-translational modification by small ubiquitin-like modifier-1 (SUMO1). CONCLUSION:PRDX1 was overexpressed in the tumor tissues of liver cancer and served as an independent poor prognostic factor for overall survival. PRDX1 can be modified by SUMO to play specific roles in hepatocarcinogenesis.
Authors: Gereon Poschmann; Michael Grzendowski; Anja Stefanski; Eva Bruns; Helmut Erich Meyer; Kai Stühler Journal: Biochim Biophys Acta Date: 2014-12-04
Authors: Joo-Heon Kim; Paul N Bogner; Sun-Hee Baek; Nithya Ramnath; Ping Liang; Hak-Ryul Kim; Chris Andrews; Young-Mee Park Journal: Clin Cancer Res Date: 2008-04-15 Impact factor: 12.531
Authors: Zheng Xu; Levina Suk Mi Lam; Lok Hei Lam; So Fun Chau; Tzi Bun Ng; Shannon Wing Ngor Au Journal: FASEB J Date: 2007-08-17 Impact factor: 5.191
Authors: Sangeeta Jaiswal; Bishnu Joshi; Jing Chen; Fa Wang; Michael K Dame; Jason R Spence; Gina M Newsome; Erica L Katz; Yatrik M Shah; Sadeesh K Ramakrishnan; Gaoming Li; Miki Lee; Henry D Appelman; Rork Kuick; Thomas D Wang Journal: Antioxid Redox Signal Date: 2021-12-21 Impact factor: 8.401
Authors: Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240